Evan Picard
Evan’s leadership journey has seen him play pivotal roles in shaping business strategies across multiple industries. Before joining MMS, Evan was Vice President of Finance at Parexel, having previously made significant contributions to renowned entities such as Syneos Health, PRA Health Sciences, and RTI International. His ability to forge strong teams and provide forward-looking insights positions him as a cornerstone of MMS’s future growth.
As Chief Financial Officer of MMS, Evan serves as the global head of the Accounting, Finance, Human Resources, and Talent Acquisition functions. Evan and his team are responsible for: financial planning and analysis, consolidations under US GAAP, treasury, HR leadership, and recruiting services. Evan’s role underscores MMS Holdings’ commitment to top-tier financial stewardship, talent development, and MMS’ growth-oriented mindset. His unique blend of experience and acumen promises to steer the company toward continued financial success.
What we have here at MMS is very special. We have great staff who deliver day in and day out for our clients and our organization. The expertise we bring to the market is top tier, and it shows through our customer satisfaction scores and our customer retention rates. In my organization, we aim to provide high quality services and solutioning for our internal and external partners. My team accomplishes this by exemplifying our corporate values, like “Wow the Customer” and “SOUL” (Sense Of Urgency Leadership). I’m very proud of the work we do at MMS and I’m excited to continue on our journey of evolution and growth as a company delivering value to our clients and bringing new therapies to patients swiftly and creatively.
Evan has a BS – Management degree from Virginia Tech (Pamplin College of Business) and an MBA from the College of William & Mary (Mason School of Business).
Suggested For You
news
May 28th, 2025
MMS Named Finalist for Fierce CRO Award in Excellence in Client Service and Partnership, CEO shortlisted for the CRO Champion Award
perspectives
May 28th, 2025
A Season of Change: Why the REMS Industry Consortium Matters More Than Ever
perspectives
May 20th, 2025
Navigating FDA OMOR Meetings: A Comprehensive Guide to Type X, Y, and Z Meetings for OTC Drug Sponsors
perspectives
May 6th, 2025
Why Clinical Trial Simulation Is Reshaping Drug Development: A Q&A with Dr. Aiden Flynn
perspectives
April 24th, 2025
How to Derisk Clinical Development with Unified Trial Design and Regulatory Strategy
perspectives
April 8th, 2025
Updated UK Clinical Trial Regulation: The Key Changes and Impact on Development Safety Update Report (DSUR) Requirements
news
April 3rd, 2025
Datacise by MMS Wins 2025 Data Breakthrough Award for Best Data Science Solution
perspectives
March 27th, 2025
Enhancing Drug Safety Through Digital Solutions: Innovative Technologies in FDA REMS Programs
news
March 19th, 2025
MMS REMS-focused Technology bolsters Full-Service REMS Solutions
webinar
April 30th, 2025
Advancing Clinical Development with Innovative Trial Design and Regulatory Strategies
perspectives
March 6th, 2025
Overview of FDA Guidance for Industry on Assessment of Ovarian Toxicity in Premenopausal Adults During Development for Oncologic Products
webinar
March 25th, 2025
Overcoming NDA/BLA Submission Challenges: Practical Strategies for Success